Catheter Precision, Inc. 8-K

What Happened

• Catheter Precision, Inc. announced the closing of a private sale (the "Series C‑4 Closing") on July 30, 2026, issuing 2,821 shares of Series C‑4 Convertible Preferred Stock at a stated value of $1,000 per share for aggregate gross proceeds of $2,821,000. The Series C‑4 Certificate of Designation was filed with the Delaware Secretary of State on July 27, 2026. Dawson James Securities, Inc. acted as placement agent.

Key Details

• 2,821 shares of Series C‑4 Convertible Preferred Stock issued; stated value $1,000/share; gross proceeds $2,821,000.
• Securities issued to participating investors exercising Additional Investment Rights under the March 9, 2026 Securities Purchase Agreement; buyers are accredited investors.
• Offering was a private transaction exempt from registration under Section 4(a)(2) and Rule 506(b) of Regulation D; no general solicitation.
• Company intends to use net proceeds for working capital, general corporate purposes, and to redeem all outstanding Series B Convertible Preferred Stock; Series C‑4 ranks senior to Common Stock for dividends and liquidation and its conversion will dilute existing Common holders.

Why It Matters

• This financing raises immediate cash ($2.821M) for operations and to redeem Series B preferred shares, which affects the company’s capital structure.
• The new Series C‑4 has senior rights over Common Stock for dividends and liquidation, and conversion into Common Stock will dilute current common shareholders’ ownership—important for investors tracking share count and potential dilution.